"Q3 demonstrated that the IPO window remained open, but not uniformly. Market volatility and issuer-specific considerations tempered activity relative to expectations and contributed to several postponements and withdrawals, reinforcing the importance of issuer preparedness, timing, and execution for companies considering a public offering."
Anne Bailey Colkitt, SVP, Head of Sales Global Capital Markets, DFIN
DFIN extends its congratulations to the 22 companies that went public through a traditional IPO, the 34 new SPACs, as well as the 13 companies that achieved public trading status post-SPAC merger, and the 7 companies that entered the market through a direct listing. During the quarter, DFIN supported companies across several of the market's most active and innovative sectors including:
- ADARx Pharmaceuticals
- Apnimed
- Attovia Therapeutics
- BlossomHill Therapeutics
- BOA Acquisition II
- B&R Technology Merger
- Electra Therapeutics
- IQM Quantum
- Jersey Mike's Subs
- Haymaker Acquisition V
- Latigo Biotherapeutics
- Londian Wason New Energy
- Lyntris
- Research Alliance IV
- Scribe Therapeutics
- SK hynix
- TCGX Acquisition
- Three Lions Acquisition
